<DOC>
	<DOCNO>NCT00147381</DOCNO>
	<brief_summary>The purpose study determine whether Campath follow Tacrolimus monotherapy effective prevention renal graft rejection ( consider acute rejection rate 5 % Campath-1H/Tacrolimus 22 % Tacrolimus/MMF/Steroids ) .</brief_summary>
	<brief_title>Effectiveness Safety Campath Combination With Tacrolimus Monotherapy Prevent Kidney Graft Rejection</brief_title>
	<detailed_description>Major advance immunosuppressive therapy result long-term graft survival use various drug combinations.However , combination carry risk e.g . infection , malignancy , renal damage , hypertension , diabetes , hyperlipidemia , hirsutism , cushingoid facial appearance bone necrosis.Therefore one major goal reduce immunosuppression without increase risk rejection . Based good result pilot study ( single acute rejection episode 18-20 month observation period despite low level Tacrolimus absence steroid ) randomise trial design evaluate safety efficacy Campath-1H .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>age 1865 endstage renal failure previous renal transplantation cadaveric donor write informed consent pregnant nursing woman multiorgan transplant recipient live donor recipient retransplants panel reactive antibody ( PRA ) &gt; 25 % previous treatment Campath1H use investigational agent within 6 week active systemic infection HIV positive patient donor positive lymphocyte cytotoxicity crossmatch recipient serum donor cell past history anaphylaxis follow exposure humanize monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Campath-1H</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>renal transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>prevention acute rejection</keyword>
</DOC>